84
Views
13
CrossRef citations to date
0
Altmetric
Original Research

The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship

, , , , , , , & show all
Pages 231-240 | Published online: 01 Dec 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jingyi Sun, Shuyuan Chu, Minyan Lu, Qilu Pan, Daofu Li, Shaojie Zheng & Libing Ma. (2020) The roles of dipeptidyl peptidase-4 and its inhibitors in the regulation of airway epithelial-mesenchymal transition. Experimental Lung Research 46:6, pages 163-173.
Read now

Articles from other publishers (12)

Derek Ge, Dinah Foer & Katherine N. Cahill. (2022) Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity. Pulmonary Therapy 9:1, pages 71-89.
Crossref
Jiaman Du, Jiewen Fu, Wenqian Zhang, Lianmei Zhang, Hanchun Chen, Jingliang Cheng, Tao He & Junjiang Fu. (2023) Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals . International Journal of Oncology 62:3.
Crossref
C. Zorampari, Anupam Prakash, Harmeet S. Rehan & Lalit K. Gupta. (2022) Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma. Pulmonary Pharmacology & Therapeutics 72, pages 102109.
Crossref
Aihua Wang, Huilin Tang, Ning Zhang & Xin Feng. (2022) Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice 183, pages 109080.
Crossref
Tianli Zhang, Xiang Tong, Shijie Zhang, Dongguang Wang, Lian Wang, Qian Wang & Hong Fan. (2021) The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence. Frontiers in Pharmacology 12.
Crossref
Shabnam Radbakhsh, Stephen L. Atkin, Luis E. Simental-Mendia & Amirhossein Sahebkar. (2021) The role of incretins and incretin-based drugs in autoimmune diseases. International Immunopharmacology 98, pages 107845.
Crossref
Yasser Albogami, Kenneth Cusi, Michael J. Daniels, Yu-Jung J. Wei & Almut G. Winterstein. (2021) Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 44:6, pages 1344-1352.
Crossref
Dinah Foer, Patrick E. Beeler, Jing Cui, Elizabeth W. Karlson, David W. Bates & Katherine N. Cahill. (2021) Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. American Journal of Respiratory and Critical Care Medicine 203:7, pages 831-840.
Crossref
Rachel S. Kelly, Kathleen A. Stringer & Chris H. Wendt. 2020. Precision in Pulmonary, Critical Care, and Sleep Medicine. Precision in Pulmonary, Critical Care, and Sleep Medicine 131 153 .
S -Y Li, H -H Chen, C -C Lai, C -L Lin & C -H Kao. (2019) Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients. QJM: An International Journal of Medicine.
Crossref
Hsin-Hung Chen, Shang-Yi Li, Weishan Chen & Chia-Hung Kao. (2019) Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes. International Journal of Environmental Research and Public Health 16:8, pages 1323.
Crossref
D. Visca, P. Pignatti, A. Spanevello, E. Lucini & E. La Rocca. (2018) Relationship between diabetes and respiratory diseases—Clinical and therapeutic aspects. Pharmacological Research 137, pages 230-235.
Crossref